Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCVS Group Regulatory News (CVSG)

Share Price Information for CVS Group (CVSG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 975.00
Bid: 970.00
Ask: 975.00
Change: 20.00 (2.09%)
Spread: 5.00 (0.515%)
Open: 947.00
High: 982.00
Low: 946.00
Prev. Close: 955.00
CVSG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Capital Markets Day

8 Nov 2022 07:00

RNS Number : 5983F
CVS Group plc
08 November 2022
 

08 November 2022

CVS Group plc

("CVS" or the "Group")

 

Capital Markets Day

 

Outlining key elements behind the Group's ambition to double EBITDA over the next five years

 

 

CVS, the AIM-quoted veterinary group and one of the UK's leading providers of integrated veterinary services, today is holding its Capital Markets Day in Rotherham. The event will set out the Group's medium term plans in support of its ambition to double EBITDA over the next 5 years.  

 

The event will cover management's highly-disciplined approach to investment and acquisitions that focuses on shareholder returns, and will highlight the following key elements of its five year ambition:

 

· Organic revenue growth of between 4% and 8% per annum;

 

· Adjusted EBITDA margin between 19% and 23% subject to mix, with the opportunity to improve practice margins through investment in facilities and equipment;

 

· Continued investment in further practice refurbishment and relocations delivering high-quality clinical care, with an opportunity to invest between £30m and £50m per annum to drive additional organic growth;

 

· Greenfield investment with plans to open three greenfield sites in the financial year to 30 June 2023 with further opportunities over the five year period;

 

· On-going opportunity to invest in technology, with the Group recently announcing a new cloud based practice management system;

 

· Continued investment in people;

 

· Acquisition opportunities in the UK and scalable international consolidation opportunities which will remain subject to our disciplined acquisition criteria with expected investment of upwards of c.£50m p.a. across the five year period;

 

· Organic operating cash conversion of > 70% with leverage (net debt / bank test EBITDA) remaining less than c.2.0x; and

 

· Sustainability and ESG remain at the heart of delivering this growth strategy.

 

There will be no new disclosures on current trading conditions, with the Group's overall performance in line with market expectations.

 

Richard Fairman, CEO, commented:

"I am delighted that the strategy set out in 2019 to focus on our organic growth augmented by acquisitions has delivered strong and robust growth for the Group. Whilst we are mindful of the macro-economic backdrop, our market is resilient and the Group remains well positioned to deliver further growth.

 

Today we set out key elements behind our ambition to double EBITDA over the next five years, by delivering our purpose of providing the best possible care to animals, and our vision to be the veterinary company people most want to work for. We will outline our plans for investment across a number of areas in support of organic and inorganic growth and margin enhancement. 

 

Combining the scope for enhanced earnings with the highly cash generative nature of our business, we believe that the Group is well placed to continue to offer attractive returns to shareholders."

 

 

The presentation and Q&A will be streamed live from 12.00pm GMT, please register via the following link https://stream.brrmedia.co.uk/broadcast/6357981498f6352ab0eba0c3

 

A copy of the presentation and a webcast recording will be available on the CVS Investor Relations website following the event.

 

 

CVS Group plc via Camarco

Richard Fairman, CEO

Ben Jacklin, COO

Robin Alfonso, CFO

 

Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418 8900

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

 

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

 

Camarco (Financial PR)

Geoffrey Pelham-Lane +44 (0)7733 124 226

Ginny Pulbrook +44 (0)7961 315 138

Toby Strong +44 (0)7789 151 644 

 

 

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is an AIM-quoted fully-integrated provider of veterinary services in the UK, with practices in the Netherlands and the Republic of Ireland. CVS is focused on providing high quality clinical services to its customers and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group has c.500 veterinary practices across its three markets, including eight specialist referral hospitals and 37 dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties), Crematoria (providing pet cremation and clinical waste disposal for CVS and third-party practices) and the Group's online retail business ("Animed Direct").

 

The Group employs c.8,100 personnel, including c.2,100 veterinary surgeons and c.3,000 nurses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBKOBPCBDDFDK
Date   Source Headline
1st May 20247:00 amRNSAppointment of Non-executive Chair
30th Apr 20247:00 amRNSTotal Voting Rights
11th Apr 20245:48 pmRNSStandard form for notification of major holdings
8th Apr 20247:00 amRNSNotice of Cyber Incident
28th Mar 20244:07 pmRNSExercise of Options and Total Voting Rights
12th Mar 20248:06 amRNSResponse to CMA update
29th Feb 20247:00 amRNSExercise of Options and Total Voting Rights
29th Feb 20247:00 amRNSInterim Results
5th Feb 202411:02 amRNSStandard form for notification of major holdings
31st Jan 20247:00 amRNSExercise of Options and Total Voting Rights
29th Jan 20243:41 pmRNSPDMR Dealing
25th Jan 20247:00 amRNSHalf year Trading Update
19th Jan 20242:24 pmRNSExercise of SAYE Options and PDMR Dealing
12th Jan 20241:56 pmRNSExercise of SAYE Options and PDMR Dealing
12th Jan 20247:00 amRNSBlock Listing Interim Review
5th Jan 20242:44 pmRNSReplacement of Director/PDMR Shareholding
5th Jan 202410:25 amRNSDirector/PDMR Shareholding
29th Dec 20237:00 amRNSExercise of Options and Total Voting Rights
22nd Dec 20237:48 amRNSBlock Listing Application
30th Nov 20237:00 amRNSExercise of Options and Total Voting Rights
29th Nov 20233:43 pmRNSResult of AGM
29th Nov 20237:00 amRNSAGM Statement and Trading Update
24th Nov 20233:56 pmRNSGrant of Options under CVS Group plc
3rd Nov 20237:05 amRNSPosting of Annual Report and Notice of AGM
31st Oct 20234:46 pmRNSExercise of Options and Total Voting Rights
27th Oct 20237:00 amRNSDirectorate Change
13th Oct 20235:21 pmRNSConfirmation of dividend dates
9th Oct 20232:58 pmRNSExercise of Options, PDMR Dealing, EBT and TVR
29th Sep 20237:00 amRNSExercise of Options and Total Voting Rights
21st Sep 20237:00 amRNSFinal results for the year ended 30 June 2023
7th Sep 202310:50 amRNSResponse to CMA review into veterinary market
31st Aug 20237:00 amRNSExercise of Options and Total Voting Rights
31st Jul 20237:00 amRNSTotal Voting Rights
27th Jul 20237:00 amRNSTrading update, AU expansion and UK acquisitions
12th Jul 20237:00 amRNSBlock Listing Interim Review and TVR Update
30th Jun 20237:00 amRNSExercise of Options and Total Voting Rights
22nd Jun 20237:00 amRNSDirectorate Change
31st May 20237:00 amRNSExercise of Options and Total Voting Rights
12th May 20234:41 pmRNSStandard form for notification of major holdings
5th May 20238:53 amRNSBlock Listing Application
2nd May 20237:00 amRNSTotal Voting Rights
31st Mar 20231:39 pmRNSHolding(s) in Company
31st Mar 20237:00 amRNSTotal Voting Rights
10th Mar 202310:37 amRNSExercise of SAYE Options, PDMR Dealing and TVR
28th Feb 20237:00 amRNSExercise of Options and Total Voting Rights
24th Feb 20237:00 amRNSInterim Results
2nd Feb 20234:42 pmRNSExercise of Options and Total Voting Rights
26th Jan 20237:00 amRNSHalf year Trading Update
11th Jan 20234:31 pmRNSBlock Listing Interim Review and TVR Update
10th Jan 202312:24 pmRNSExercise of SAYE Options and PDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.